Providing due diligence in neurology


A venture capital investor needed an assessment of the technical, regulatory and market risks in a neuroscience specialty pharma company developing a range of products through the 505 (b)(2) regulatory pathway.


We gave an assessment of the likely investor returns under two possible scenarios, and advised on the most likely exit triggers/timings. The client expressed a high level of satisfaction with our work.

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Stay in touch